No evidence so far for the dissemination of carbapenemase-producing Enterobactericeae in the community in Switzerland

Antimicrobial Resistance and Infection Control

Roger Stephan¹  Herbert Hächler¹  Katrin Zurfluh¹  Magdalena Nüesch-Inderbinen¹ 

[1]National Centre for Enteropathogenic Bacteria and Listeria, Institute for Food Safety and Hygiene, Vetsuisse Faculty University of Zurich, Winterthurerstrasse 272, 8057 Zurich, Switzerland

关键词: Healthy carriers;    Enterobacteriaceae;    Dissemination;    Carbapenemase;   

Others  :  790779
DOI  :  10.1186/2047-2994-2-23

 received in 2013-03-21, accepted in 2013-09-01,  发布年份 2013

【 摘 要 】

Background

Carbapenemase-producing Enterobacteriaceae represent an increasing threat to public health and to the treatment of serious nosocomial infections. The aim of this study was to screen for the presence of carbapenemase-producing Enterobacteriaceae in human carriers in community settings in Switzerland, a country representative of central Europe.

Findings

Three hundred and fourteen stool samples of healthy staff members of a meat-processing company and 291 fecal swabs from primary care patients were recovered in Switzerland between April 2012 and July 2012 and were tested for carbapenemase-producing Enterobacteriaceae isolates by selecting for growth on a carbapenem-containing selective medium. Six resulting isolates (5 Escherichia coli and 1 Citrobacter youngae) were subjected to antimicrobial susceptibility tests and PCR analysis by screening for the carbapenemase genes bla_OXA-48, bla_VIM, bla_NDM-1, and bla_KPC as well as for the extended-spectrum ß-lactamase genes bla_TEM,bla_SHV, bla_CTX-M and bla_CMY-2. No carbapenemase genes were detected. Resistance to ß-lactam antibiotics was due to carriage of the extended-spectrum ß-lactamase CTX-M-15 in 4 isolates, to CTX-M-14 in one further isolate and to the plasmidic AmpC-ß-lactamase CMY-2 in one isolate.

Conclusions

These results show that carbapenemase-producing Enterobacteriaceae are as yet not present in the community. Continuous surveillance is necessary to anticipate future trends in the prevalence and dissemination of carbapenem resistant isolates in the population.

【 授权许可】

   
2013 Nüesch-Inderbinen et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Akova M, Daikos GL, Tzouvelekis L, Carmeli Y: Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012, 18:439-448.
• [2]Ambler RP, Coulson AF, Frère JM, Ghuysen JM, Joris B, Forsman M, Levesque RC, Tiraby G, Waley SG: A standard numbering scheme for the class A beta-lactamases. Biochem J 1991, 276:269.
• [3]Nordmann P, Naas T, Poirel L: Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798.
• [4]Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, Vatopoulos A, Gniadkowski M, Toth A, Pfeifer Y, Jarlier V, Carmeli Y, CNSE Working Group: Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010., 15(46)
• [5]Filippini M, Masiero G, Moschetti K: Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health Policy 2006, 78:77-92.
• [6]Plüss-Suard C, Pannatier A, Kronenberg A, Mühlemann K, Zanetti G: Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe. J Hosp Infect 2011, 79:166-171.
• [7]Poirel L, Lienhard R, Potron A, Malinverni R, Siegrist HH, Nordmann P: Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in a Klebsiella pneumoniae isolate from Switzerland. J Antimicrob Chemother 2011, 66:675-676.
• [8]Babouee B, Widmer AF, Dubuis O, Ciardo D, Droz S, Betsch BY, Garzoni C, Führer U, Battegay M, Frei R, Goldenberger D: Emergence of four cases of KPC-2 and KPC-3-carrying Klebsiella pneumoniae introduced to Switzerland, 2009–10. Euro Surveill 2011., 16(11)
• [9]Poirel L, Schrenzel J, Cherkaoui A, Bernabeu S, Renzi G, Nordmann P: Molecular analysis of NDM-1-producing enterobacterial isolates from Geneva, Switzerland. J Antimicrob Chemother 2011, 66:1730-1733.
• [10]Potron A, Schrenzel J, Poirel L, Renzi G, Cherkaoui A, Nordmann P: Emergence of OXA-48-producing Enterobacteriaceae in Switzerland. Int J Antimicrob Agents 2012, 40:563-564.
• [11]Nüesch-Inderbinen MT, Abgottspon H, Zurfluh K, Nüesch HJ, Stephan R, Hächler H: Cross-sectional study on fecal carriage of Enterobacteriaceae with resistance to extended-spectrum cephalosporins in primary care patients. Microb Drug Resistin press
• [12]Poirel L, Walsh TR, Cuvillier V, Nordmann P: Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 2011, 70:119-123.
• [13]Ellington MJ, Kistler J, Livermore DM, Woodford N: Multiplex PCR for rapid detection of genes encoding acquired metallo-β-lactamases. J Antimicrob Chemother 2007, 59:321-322.
• [14]Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing. Wayne; 2011. [Twenty-first informational supplement, CLSI document M100-S21 2008]
• [15]Geser N, Stephan R, Korczak BM, Beutin L, Hächler H: Molecular identification of extended-spectrum-β-lactamase genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland. Antimicrob Agents Chemother 2012, 56:1609-1612.
• [16]Briñas L, Moreno MA, Zarazaga M, Porrero C, Sáenz Y, García M, Dominguez L, Torres C: Detection of CMY-2, CTX-M-14, and SHV-12 β-lactamases in Escherichia coli fecal-sample isolates from healthy chickens. Antimicrob Agents Chemother 2003, 47:2056-2058.
• [17]Endimiani A, Rossano A, Kunz D, Overesch G, Perreten V: First countrywide survey of third-generation cephalosporin-resistant Escherichia coli from broilers, swine, and cattle in Switzerland. Diagn Microbiol Infect Dis 2012, 73:31-38.
• [18]Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P: Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007, 13:315-317.
• [19]Stapleton PD, Shannon KP, French GL: Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999, 43:1206-1210.